Healthcare
Alaunos Therapeutics, Inc.(TCRT)
Live Price
Offline$2.15
-3.15% today
1Y Change
-52.01%
Window
Jun 23, 2025 โ Jun 18, 2026
- Market Cap
- $10.00M
- Revenue Growth
- -50.0%
- EPS Growth
- +24.7%
- Dividend Yield
- 0.0%
Coverage: 249 bars ยท Jun 23, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Alaunos Therapeutics, Inc. (TCRT) is a Healthcare stock with a market cap of $10.00M and listed on NASDAQ. The stock last traded around $2.15 and down 52.0% across the available one-year price window (Jun 23, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of -50.0%, EPS growth of +24.7%, a dividend yield of 0.0%. What stands out right now is revenue -50.0%, EPS +24.7%, free cash flow +40.3% with operating margin -84500.0% and ROIC -196.2%. Valuation already assumes a fairly strong business story at price/sales 1241.4. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines TCRT price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-50.0% vs +7.6% peer median
Operating Margin
Below sector median
-84500.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 15, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -50.0% and EPS is at +24.7%, with operating margin around -84500.0%.
The next real check-in already has a date
The next earnings event is scheduled for Aug 18, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +2.0% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 15, 2026 | โ | -0.4% | -2.0% | -7.7% |
2026 Mar 31, 2026 | +89.2% | +3.1% | +1.7% | -10.5% |
2025 Nov 14, 2025 | +88.8% | +8.4% | +6.4% | +41.8% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TCRT
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
TCRT Max Drawdown
-65.50%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for TCRT and SPY.
Company Overview
Alaunos Therapeutics, Inc.
NASDAQ Global Select
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor platform; and mbIL-15 to treat solid tumors. Alaunos Therapeutics, Inc. has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; and a patent license agreement, and research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022. Alaunos Therapeutics, Inc. is headquartered in Houston, Texas.
- Leadership
- Holger Weis
- IPO Date
- Aug 24, 2005
- Employees
- 1
- Street Address
- 8030 El Rio Street
- Mailing
- Houston, TX, 77054
- Region
- Houston, TX, US
- Reporting Currency
- USD
- Investor Line
- 346 355 4099
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 1241.4
- Price/Book
- 2.4
Growth
- Revenue
- -50.0%
- EPS
- +24.7%
- Free Cash Flow
- +40.3%
Profitability
- Gross Margin
- -3600.0%
- Operating Margin
- -84500.0%
- Net Margin
- -83520.0%
- ROE
- -172.7%
- ROIC
- -196.2%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 2.45
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.